Cardiovascular Innovation Led by Dr. Hung-Fat Tse
OmisHeart Biotechnology
From Treatment to Renewal: Next-Gen Cardiac Therapeutics
Chief Cardiologist & Clinician-Scientist
With over 800 peer-reviewed publications, he combines scientific leadership with clinical execution, accelerating therapies from bench to patient
His vision translating 25+ years of clinical cardiology and regenerative science into scalable, life-saving therapies.
Advancing next-generation cardiovascular therapeutics through innovative stem cell, iPSC, exosome, MSC, and organoid technologies.
Dr. Hung Fat Tse
Founder & CEO, OmisHeart
Prof. Hung-Fat Tse, MBBS, MD, PhD, FRCP (Edin, Glasg, Lond), FHKCP, FHKAM(Med), FACC, FESC Professor, Chair of Cardiovascular Medicine; William MW Mong Professor in Cardiology Professor, Dr. Li Dak-Sum Research Centre Chairperson, Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong Chief of Service, Department of Medicine, Queen Mary Hospital Chief, Cardiology Division, Department of Medicine; Queen Mary Hospital, The University of Hong Kong, Hong Kong Co-director, Cardiac and Vascular Center, The University of Hong Kong- Shenzhen Hospital Honorary Consultant in Cardiology, QMH/TWH/HKSH/GHK/HKU-SZ Academic lead, HKUMed Laboratory of Cellular Therapeutics, The University of Hong Kong
LAMP2B: Unlocking the Cell’s Full Recycling Power
LAMP2B therapy restores the cell's natural ability to clean itself clearing out disease-causing waste and renewing the body from the inside out.
Autophagy
2016 Nobel Prize: Yoshinori Ohsumi Unraveling
Our Technology
The master key to cardiac renewal and timeless health.
We Restore the Cell's Recycling Power
Our Expertise
Precision-engineered. Data-proven platforms
modRNA
Restores key proteins needed for recycling
Exosomes
Deliver these proteins straight into damaged cells
Regenerative Patches
Support long-term repair and recovery
Custom Technology Solutions
Tailored Strategies
Our Innovations
Showcasing Technological Innovations
Development Pipeline:
Driving the Next Generation of Cardiac Therapeutics
Targeting Danon Disease:
For severe monogenic diseases with catastrophic natural histories, regulatory pathways like Fast Track and Accelerated Approval are designed to streamline clinical entry and compress development timelines.
Ready to Explore Innovative Solutions?
Contact Us
